Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Pediatrics and Neonatology
  • Pediatrics and Neonatology News
  • Timing of RSV...

Timing of RSV Immunization Matters for Infant Protection suggests study

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2025-05-05T20:30:17+05:30  |  Updated On 5 May 2025 8:30 PM IST
Timing of RSV Immunization Matters for Infant Protection suggests study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in JAMA Network Open.

Nirsevimab is a seasonal immunization that targets RSV in infants. As a monoclonal antibody-a protein that can bind to a specific target-nirsevimab binds to a particular area of the virus and blocks RSV from entering human cells.

In a new study testing the effectiveness of the monoclonal antibody in a real-world setting, researchers at Yale School of Medicine (YSM) found that immunization was up to 85% effective at preventing serious illness in children under one year of age. However, timing its administration to coincide with seasonal outbreaks is important because the monoclonal antibody’s effectiveness waned three months after receiving the shot.

Children with severe RSV “are essentially drowning in their own mucus,” says Carlos Oliveira, MD, PhD, assistant professor of pediatrics (infectious diseases) at YSM and senior author of the study. So having immunizations that can prevent this and keep vulnerable infants from ending up in the hospital “is huge,” he says.

A dangerous disease

RSV is incredibly common. Almost every child will contract the virus before the age of two. Some people who get RSV only develop a runny nose and fever. But for infants and elderly patients, the virus can be deadly.

“Any parents of a baby with severe RSV will see how their child is constantly struggling to breathe,” says Oliveira, who is also an assistant professor of biostatistics at Yale School of Public Health. Excessive mucus produced to fight off the virus can clog the small airways of children under the age of six months. Globally, around 1.4 million children under the age of six months end up hospitalized due to RSV every year, mostly during the fall and winter. Of those, approximately 27,000 will die.

There is no targeted treatment for RSV. But in July 2023, the U.S. Food and Drug Administration (FDA) licensed nirsevimab as the first single-dose, long-acting monoclonal antibody for the prevention of RSV in infants. Previously, palivizumab was the only preventative option and required monthly injections to sustain its protective effect.

Clinical trials found nirsevimab to be safe and effective for infants. This study is an important continuation of that research. Vaccines and medications are still studied after FDA approval to track their effectiveness in the general population-outside of the clinical trial setting-and further inform optimal use. These types of studies are considered phase IV trials.

RSV immunization prevents severe illness

Oliveira and his colleagues collected data on approximately 3,000 infants who received care in the Yale New Haven Health System for respiratory illnesses between October 2023 and May 2024. This was the first RSV season in which nirsevimab was available, and only 10% of infants in the study had received the immunization before seeking medical help.

Of the 3,000 infants, the researchers tracked who had tested positive for RSV, who had been immunized, and how they fared across the study period. About 680 infants tested positive for RSV, and 166 infants-97% of whom had not been vaccinated with nirsevimab-ended up hospitalized.

The data showed that the monoclonal antibody didn’t provide total protection against RSV; nirsevimab was around 68% effective at preventing RSV infection in infants. However, the researchers found that immunization was 85% effective at preventing infants from being hospitalized.

So, while nirsevimab didn’t prevent all RSV infections, “the key takeaway is that the monoclonal antibody was very good at preventing severe disease,” says Oliveira. Immunization was the difference between an infant with a runny nose and one that ended up in the ICU.

Oliveira and his colleagues’ research also shows that nirsevimab becomes less effective after about 14 weeks. The U.S. Centers for Disease Control and Prevention recommends that infants who are eight months old or younger receive the shot at the very start of the RSV season, which runs between October and March.

Information from Oliveira’s study will help policymakers decide when to roll out nirsevimab during the RSV season.

Reference:

Xu H, Aparicio C, Wats A, et al. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Netw Open. 2025;8(3):e250380. doi:10.1001/jamanetworkopen.2025.0380

JAMA Network Openrespiratory syncytial virusnirsevimab
Source : JAMA Network Open
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

View All

Journal Club Today

Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

View All

Health News Today

Health Bulletin 31/May/2025

Health Bulletin 31/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok